In addition, GLP-1/glucose-dependent insulinotropic peptide (GIP)-1 dual agonists are a relatively new class of medications that have shown promise in NAFLD treatment [18,19]. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.